BR112022012093A2 - Anticorpos contra integrina alfa 11 beta 1 - Google Patents

Anticorpos contra integrina alfa 11 beta 1

Info

Publication number
BR112022012093A2
BR112022012093A2 BR112022012093A BR112022012093A BR112022012093A2 BR 112022012093 A2 BR112022012093 A2 BR 112022012093A2 BR 112022012093 A BR112022012093 A BR 112022012093A BR 112022012093 A BR112022012093 A BR 112022012093A BR 112022012093 A2 BR112022012093 A2 BR 112022012093A2
Authority
BR
Brazil
Prior art keywords
integrin alpha
beta
antibodies
antibodies against
against integrin
Prior art date
Application number
BR112022012093A
Other languages
English (en)
Inventor
Kurtagic Elma
W Iii Meador James
Beneduce Christopher Jr
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BR112022012093A2 publication Critical patent/BR112022012093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS CONTRA INTEGRINA ALFA 11BETA 1. A presente invenção refere-se a anticorpos que especificamente se ligam a integrina alfa 11 beta 1 (a11ß1), bem como métodos de preparação e uso de tais anticorpos. Em algumas modalidades, um anticorpo anti-a11ß1, ou fragmento de ligação ao antígeno do mesmo, é um anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo. A presente invenção também fornece uso de tais anticorpos para tratar distúrbios fibróticos e/ou cânceres.
BR112022012093A 2019-12-20 2020-12-18 Anticorpos contra integrina alfa 11 beta 1 BR112022012093A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
BR112022012093A2 true BR112022012093A2 (pt) 2022-08-30

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012093A BR112022012093A2 (pt) 2019-12-20 2020-12-18 Anticorpos contra integrina alfa 11 beta 1

Country Status (17)

Country Link
US (1) US20230050972A1 (pt)
EP (1) EP4076525A4 (pt)
JP (1) JP2023508286A (pt)
KR (1) KR20220123013A (pt)
CN (1) CN115135342A (pt)
AU (1) AU2020407124A1 (pt)
BR (1) BR112022012093A2 (pt)
CA (1) CA3165386A1 (pt)
CL (1) CL2022001673A1 (pt)
CO (1) CO2022010204A2 (pt)
CR (1) CR20220288A (pt)
DO (1) DOP2022000129A (pt)
EC (1) ECSP22056627A (pt)
IL (1) IL294047A (pt)
MX (1) MX2022007521A (pt)
PE (1) PE20221723A1 (pt)
WO (1) WO2021127500A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230121831A (ko) * 2020-12-18 2023-08-21 모멘타 파머슈티컬스 인코포레이티드 인테그린 알파 11 베타 1에 대한 항체
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2023250415A2 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US20110256061A1 (en) * 2006-12-18 2011-10-20 Evy Lundgren-Akerlund Binding agents to the Integrin Alpha-11 subunit, and uses thereof
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3760722A4 (en) * 2018-03-01 2021-11-24 Hiroshima University MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND ASSOCIATED USE

Also Published As

Publication number Publication date
KR20220123013A (ko) 2022-09-05
MX2022007521A (es) 2022-07-19
IL294047A (en) 2022-08-01
US20230050972A1 (en) 2023-02-16
CL2022001673A1 (es) 2023-02-03
CA3165386A1 (en) 2021-06-24
CR20220288A (es) 2022-10-07
EP4076525A1 (en) 2022-10-26
JP2023508286A (ja) 2023-03-02
DOP2022000129A (es) 2022-10-31
CO2022010204A2 (es) 2022-10-21
AU2020407124A1 (en) 2022-07-21
CN115135342A (zh) 2022-09-30
WO2021127500A9 (en) 2021-07-29
PE20221723A1 (es) 2022-11-04
ECSP22056627A (es) 2022-11-30
EP4076525A4 (en) 2024-05-01
WO2021127500A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
BR112022012093A2 (pt) Anticorpos contra integrina alfa 11 beta 1
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12019502459A1 (en) Anti-trem2 antibodies and methods of use thereof
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
BR112017002342A2 (pt) novos anticorpos e usos dos mesmos
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
BR112018002877A2 (pt) anticorpos anti-receptor ccr7 humanizados
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
BR112019008279A2 (pt) uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
ZA202008095B (en) Humanized antibodies against psma
CO2021008204A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso